SWITZERLAND - EdRIP et al. invest CHF 38m into Endosense
Edmond de Rothschild Investment Partners (EdRIP) has led a series-B funding round worth over CHF 38m for medical technology company Endosense SA, alongside Gimv, Neomed, VI Partners, Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie.
The financing allows Endosense to commercialise its product, TactiCath, in the European market and start clinical studies in America.
Founded in 2003, Geneva-headquartered Endosense focuses on catheter ablation for treating cardiac arrhythmias. Catheter ablation is a treatment whereby a special catheter is advanced into the patient's left heart chamber via the femoral vein.
The company previously received a CHF 22.6m round in 2005.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds








